Form 4: Palvella Therapeutics CFO and Treasurer Granted Stock Options

Matthew E. Korenberg, CFO and Treasurer of Palvella Therapeutics, received incentive and non-qualified stock options on February 5, 2025.

Summary

• Matthew E. Korenberg, CFO and Treasurer of Palvella Therapeutics, was granted stock options on February 5, 2025.
• The grant includes incentive stock options for 5,373 shares and non-qualified stock options for 123,559 shares.
• The exercise price for both types of options is $14.76 per share.
• The options vest in equal monthly tranches over 48 months and expire on February 5, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates ongoing compensation practices.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for CFOs in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant (128,932 options total) would need to be compared to grants at peer companies of similar market capitalization and stage of development to assess its relative value.
• Vesting schedules of 48 months are typical for such grants, aligning executive incentives with long-term company performance.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders.
• The grant incentivizes the CFO to work towards increasing shareholder value.

Key Dates